Ionis Reports Q3 2026 Results, Lowers TRYNGOLZA Sales Guidance
Ionis reported Q3 2026 revenue of $243M, up from $157M YoY, with a GAAP net loss of $110M. The company lowered TRYNGOLZA sales guidance to ~$50M but reaffirmed total revenue and cash guidance. Cash reserves were $1.9B at quarter-end. Pipeline updates include positive regulatory opinions and study progress.
How this was made
The 30-second read
Why it matters
The guidance reduction is the primary market-moving element, likely prompting a sell-off in IONS shares.
Market read
Earnings release with guidance change provides immediate trading signal for IONS.
What to watch
Strong cash position of $1.9B provides runway for continued R&D and potential acquisitions.
Background
Ionis Pharmaceuticals reported Q3 2026 results with revenue growth but widened losses and lowered sales guidance for its TRYNGOLZA product.
Ticker impact
Ionis lowered its TRYNGOLZA sales guidance to $50M and reaffirmed revenue guidance, indicating weaker product performance.
likely downside as market prices in reduced sales outlook
Guidance revisions are material for a biotech; investors typically react negatively to lowered product sales forecasts.
Market effects
Other biotech peers may see relative strength as investors rotate away from Ionis.
US biotech sector may face slight pressure in after-hours trading.
Limited to investors tracking RNA therapeutics and rare disease pipelines.
Counterpoint
If TRYNGOLZA regulatory approval proceeds smoothly, the guidance cut may be temporary and could present a buying opportunity.
Key entities
- CompanyIonis Pharmaceuticals
US-listed biotech firm (ticker IONS) focusing on RNA therapeutics.
